比利时联合化工集团(UCB)    
比利时联合化工集团(UCB)是比利时一家大型医药化工企业。公司创立于1928年，总部设在布鲁塞尔市，目前集团下属共有150余家子公司，分布在世界各地，共有雇员近万名。

比利时联合化工企业有限公司(UCB)是一家具有百年悠久历史的跨国公司，主要业务涉及医药、特种化工和薄膜。1995年中国代表处在上海正式成立。1997年中国药品部成立，着重从事处方药品的开发、生产和销售，特别在开发研究上的大量投入，使得产品在其涉足的领域,包括变态反应系统、中枢神经系统和心血管系统保持领先地位。尤其是UCB皇冠上两颗熠熠生辉的明珠－仙特明和脑复康。它们被欧美、日本等一百多个国家批准销售，受到了全球医药界的瞩目。

集团的业务分为三大部分：药品部、化工部和薄膜部。2001年集团总营业额为24.75亿欧元，比上年增加了12%，净利润3.18亿欧元，增长了18%。其中药品部营业额达14.27亿欧元，化工部营业额6.52亿欧元，薄膜部营业额3.96亿欧元。该集团95%的产品销往国外，公司的主要业务在欧洲，销售额占55%，美国的销售额占24%，亚洲占19%。

集团以创新和全球化作为自己的经营战略，每年投入大量的研究开发费用，生产自己开发的新产品，并尽快占领国际市场，2000年集团研发费用达1.82亿欧元。在经营管理方面，集团总部负责产品的研究开发、人员的培训以及确定战略目标，各子公司则拥有较大的自主权，可根据当地的市场发展变化制定相应的销售战略。这种灵活的组织形式，使集团有很强的应变能力，并能随时掌握市场的脉搏。该集团始终坚持生产销售附加值高的产品。他们所涉足的领域往往在世界上处于领先地位。如他们生产销售的抗过敏药ZYRTEC，是欧洲市场上销售最多的抗过敏药。他们生产销售的调节人体大脑活动的药物NOOTROPIL也是世界著名的药物之一。此外，其化工部生产的RADCURE树脂，年产量达6万多吨，为世界第一大生产商，占领了世界市场35%的份额；CRYLCOAT树脂，年产量达9万多吨，为世界第一大生产商，占领了世界市场30%的份额；再如甲胺及其产品，年产量达26万多吨，占领了世界市场20%的份额。薄膜部生产的两大类产品也在世界市场上占有重要地位。如聚丙烯双向膜PROPAFILM，为世界第六大生产商，年产量为7.5万吨。该集团还是世界最大玻璃纸生产商，年产玻璃纸6万吨，用于各种包装。

比利时联合化工集团积极发展与中国的业务联系，并在中国投资了1000万美元，在上海奉贤与上海凤凰自行车集团合资建立了树脂生产厂和饲料厂各一家。

Scientific and technological advances have created a new opportunity to address the complex interconnections of severe diseases much more effectively.

We call this opportunity ‘the next generation biopharma leader'. And we are rapidly bringing it to life, it is about:

Connecting science in new waysBy integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.

The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition.Cimzia®, our most advanced New Biological Entity (NBE), targeted at Crohn's disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.Connecting peopleIn a knowledge- and ideas-based industry like ours, human capital is the lifeblood of success. To unlock the creative potential of our global team of over 10,000 staff and our 30-plus partners, we are creating a networked, cross-functional organisation.

UCB People, an innovative intranet tool, links our knowledge and skills. Our virtual R&D collaboration platform, based on the principles of Wikipedia, is another example.Multi-disciplinary teams are working on all development projects, including members of R&D, supply chain and sales, as well as partners and patients...Connecting patientsSevere diseases, such as Epilepsy, Crohn's or Parkinson's, tend to be "silent diseases" - sufferers are often socially stigmatised and reluctant to share their experiences and insights. To overcome this problem, we are creating novel and personal ways for patients and their families to connect, virtually and live, with each other, us, our partners and opinion formers.

The "CrohnsandMe.com" community is one such exampleThe sponsorship of a Pearl Jam concert demonstrates our commitment to raise awareness of severe diseasesPatients and their families are regularly invited to discuss the daily realities of their diseases with our staff, partners and key opinion informers - providing invaluable insights.
A global biopharma focused on severe diseases
with operations in more than 40 countries and global revenue of €3.6 billion in 2008A leader in allergy and epilepsy
with 11 large and small molecules in the pipeline, spanning 13 diseases, from Crohn's and Parkinson's to multiple sclerosis.A leader in antibody research
supported by proprietary chemistry and over 30 major R&D partners.